KIT and metastatic melanoma: To date, approximately 10 registered clinical trials have explored the safety and efficacy of Imatinib alone or with other agents in metastatic melanoma, however majority of the studies were not successfully completed.[13] One of which was an early phase trial of Pembrolizumab and Imatinib in patients with c-Kit mutations.